Background: A treatment-related fluctuation (TRF) in a patient with Guillain-Barré syndrome (GBS) is defined as clinical deterioration within two months of symptom onset following previous stabilization or improvements with treatment. Objective: To investigate the clinical characteristics and factors that could increase the risk of relapse of GBS in patients with and without TRFs. Methods: Retrospective review of medical records of patients (>18 years) with GBS evaluated between January/2006 and July/2019. Demographic and clinical characteristics, ancillary studies, treatment received, and the clinical course of patients with and without TRFs were analyzed. Results: Overall, 124 cases of GBS were included; seven (5.6%) presented TRFs. GBS-TRF cases were triggered more frequently by infectious mononucleosis (28.57 vs. 8.55%; p=0.01). GBS-TRF were initially treated with plasmapheresis more frequently than those without TRF (14.29 vs. 1.70%; p=0.0349). Combined treatment (71.43 vs. 4.27%; p<0.001) and corticosteroids (42.86 vs. 1.71%; p<0.001) were more commonly used in the GBS-TRF group. GBS-TRF patients presented a higher median initial disability score (4 vs. 2; p=0.01). Conclusions: Patients with GBS triggered by infectious mononucleosis and a high degree of initial disability have higher chances of developing TRFs. Although patients with TRF were treated with plasmapheresis more often, the total number was too low to suggest a link between plasma exchange and TRF. Keywords: Cytomegalovirus; Herpesvirus Human 4; Guillain-Barré Syndrome; Infectious Mononucleosis.

RESUMEN
Antecedentes: Una fluctuación relacionada al tratamiento (FRT) en un paciente con síndrome de Guillain-Barré (SGB) se define como un deterioro clínico dentro de los dos meses posteriores al inicio de los síntomas después de una estabilización previa o mejora con el tratamiento. Objetivo: Investigar las características clínicas y los factores que podrían incrementar el riesgo de recaída, comparando pacientes con SGB, con y sin FRT. Métodos: Revisión retrospectiva de historias clínicas de pacientes (>18 años) con SGB evaluados entre enero/2006 y julio/2019. Se analizaron las características demográficas y clínicas, los estudios complementarios, el tratamiento recibido y la evolución clínica de los pacientes con y sin FRT. Resultados: Se incluyeron 124 casos de SGB en el total; 7 (5,6%) presentaron FRT. Los casos de SGB con FRT se desencadenaron con mayor frecuencia por mononucleosis infecciosa (28,57 vs. 8,55%; p=0,01). Los casos de SGB con FRT se trataron inicialmente con plasmaféresis con más frecuencia que aquellos sin FRT (14,29 vs. 1,70%; p=0,0349). El tratamiento combinado (71,43 vs. 4,27%; p<0,001) y los corticosteroides (42,86 vs. 1,71%; p<0,001) se utilizaron con mayor frecuencia en el grupo de SGB con FRT. Los pacientes con FRT presentaron una escala de discapacidad inicial mediana más alta (4 vs. 2; p=0,01). Conclusions: Aquellos SGB desencadenados por mononucleosis infecciosa y un alto grado de discapacidad inicial tienen una mayor probabilidad de desarrollar FRT. Aunque los pacientes con FRT fueron tratados con plasmaféresis con mayor frecuencia, el número total fue demasiado bajo para sugerir un vínculo entre la plasmaféresis y FRT. Palabras claves: Citomegalovirus; Herpesvirus Humano 4; Síndrome de Guillain-Barré; Mononucleosis Infecciosa.
INTRODUCTION

Treatment-related fluctuation (TRF) in patients with Guillain-Barré syndrome (GBS) describes those cases in which clinical deterioration occurs one or more times after initial improvement or stabilization with intravenous immunoglobulin (IVIg) or plasmapheresis (PE) treatment within the first two months after the onset of symptoms (Figure 1). This phenomenon affects 5–26% of patients with GBS. Currently, the underlying physiological processes and risk factors related to TRFs are unknown. These mechanisms could vary according to geographical area, due to the different clinical phenotypes or electrophysiological subtypes.

The objective of our work was to investigate the clinical characteristics and factors that could increase the risk of relapse by comparing patients with GBS with and without TRFs.

METHODS

Clinical charts of consecutive patients aged ≥18 years and diagnosed with GBS between January 2006 and July 2019 in our center (FLENI, Buenos Aires, Argentina) were retrospectively analyzed. The study was approved by the institutional ethics committee.

Demographic characteristics and past medical history were recorded. Infectious symptoms or vaccine administration occurring up to one-month before symptom onset were considered disease triggers. Infectious mononucleosis was considered in cases of fever, pharyngitis, and adenomegaly due to Epstein-Barr virus (EBV), cytomegalovirus (CMV), or HIV.

Clinical manifestations assessed were pain, motor and sensory deficits, autonomic dysfunction, and cranial nerve involvement. The Medical Research Council-Sum Score (MRC-Sum Score) was used to assess motor alterations. Autonomic dysfunction was only considered when clinical precipitants that could explain these manifestations were ruled out. An initial cardiovascular evaluation was performed in all patients until clinical stability was verified. Hemodynamic monitoring was performed four times a day in clinically stable patients, while those unstable remained in the intensive care unit (ICU) under continuous cardiovascular monitoring.

Lumbar puncture (LP) and cerebrospinal fluid (CSF) analysis were performed in all patients during acute illness. Albuminocytologic dissociation was considered present when CSF-protein level was increased (>45 mg/dL), without CSF-pleocytosis (leukocyte count of <10/mm³).

All patients underwent electrophysiological nerve conduction studies at least once within the first four weeks from the onset of symptoms. Amplitude and conduction velocity were measured after stimulation at conventional sites. Electrophysiological patterns were classified as demyelinating, axonal, or undetermined/normal.

Established treatment and delay in administration were analyzed. Disability was assessed at admission, and 6 and 12 months using the GBS Disability Scale proposed by Hughes.

A TRF was defined as: a) improvement in the GBS disability score of at least one grade or improvement in the MRC sum score of more than 5 points after treatment completion, followed by a decline in the GBS disability score of at least one grade or a reduction in the MRC sum score of more than 5 points within the first month after the onset of symptoms; or b) steady clinical course for more than one week after treatment completion, followed by a decline of at least one grade of the GBS disability score or more than 5 points on the MRC sum score.

Patients who had ≥3 TRFs or progressed clinically after two months from the onset of motor symptoms were excluded and classified as Acute-onset Chronic Inflammatory Demyelinating Polyneuropathy (A-CIDP).

Differences in demographic and clinical characteristics, ancillary studies, treatment, and clinical course between both groups were compared using the Wilcoxon rank-sum test (Stata13v). An alpha value of 0.05 was considered statistically significant.

RESULTS

A total of 124 patients with GBS were included. Seven patients (5.64%) presented TRFs, with a median age of 53 years (range 32-81 years) and a slight male predominance (57.14%). There were no significant differences in sex and age among GBS patients with and without TRFs (Table 1). A-CIDP patients were excluded (Figure 2). Patients with subacute inflammatory demyelinating polyneuropathy (SIDP) and other variants of CIDP were also excluded.
| Demographic data                                      | Total (n=124) | GBS without TRF (n=117) | GBS with TRF (n=7) | p-value |
|------------------------------------------------------|---------------|--------------------------|--------------------|---------|
| Age in years; median (range)                         | 48 (21–86)    | 48 (21–86)               | 53 (32–81)         | 0.51    |
| Men; n (%)                                           | 71 (57.26)    | 67 (57.26)               | 4 (57.14)          | 0.99    |
| Diabetes mellitus; n (%)                             | 11 (8.87)     | 9 (7.69)                 | 2 (28.57)          | 0.06    |
| Autoimmune disease; n (%)                            | 28 (22.58)    | 27 (23.08)               | 1 (14.29)          | 0.59    |
| Facial paralysis; n (%)                              | 8 (6.45)      | 7 (5.98)                 | 1 (14.29)          | 0.38    |
| Oncological disease; n (%)                           | 10 (8.06)     | 9 (7.69)                 | 1 (14.29)          | 0.53    |
| HIV; n (%)                                           | 5 (4.07)      | 5 (4.31)                 | 0                  | 0.57    |
| Triggers; n (%)                                      | 86 (69.35)    | 82 (70.08)               | 4 (57.14)          | 0.47    |
| Respiratory infection; n (%)                         | 41 (33.06)    | 40 (34.19)               | 1 (14.29)          | 0.27    |
| Acute diarrhea; n (%)                                | 31 (25.00)    | 30 (25.64)               | 1 (14.29)          | 0.50    |
| Infectious mononucleosis; n (%)                      | 8 (6.45)      | 6 (5.12)                 | 2 (28.57)          | 0.01*   |
| Vaccination; n (%)                                   | 2 (1.61)      | 2 (1.71)                 | 0                  | 0.72    |
| Others; n (%)                                        | 4 (3.22)      | 4 (3.41)                 | 0                  | 0.62    |
| Time from trigger to the first symptom; median days (range) | 10 (1–30)  | 10 (1–30)               | 5 (3–10)           | 0.10    |
| Time from trigger to weakness; median days (range)   | 11(1–40)      | 11(1–40)                 | 7(3–37)            | 0.48    |
| Clinical manifestations                               |               |                          |                    |         |
| Neuropathic pain; n (%)                              | 78 (62.9)     | 71 (60.68)               | 7 (100)            | 0.03*   |
| Neck MRC; median (range)                             | 5 (0–5)       | 5                         | 4                  | 0.86    |
| Worst MRC-Sum Score; median(range)                   | 51 (0–60)     | 51                        | 50                 | 0.78    |
| Sensory disturbances; n (%)                          | 110 (88.71)   | 104 (88.89)              | 6 (85.71)          | 0.79    |
| Paresthesia; n (%)                                   | 94 (77.69)    | 87 (76.32)               | 7 (100)            | 0.14    |
| Cutaneous sensory; n (%)                             | 50 (41.32)    | 46 (40.35)               | 4 (57.14)          | 0.38    |
| Proprioceptive sensory; n (%)                        | 44 (36.36)    | 42 (36.84)               | 2 (28.57)          | 0.66    |
| Sensory ataxia; n (%)                                | 25 (20.16)    | 23 (19.66)               | 2 (28.57)          | 0.56    |
| Osteotendinous reflexes                              |               |                          |                    |         |
| Generalized areflexia; n (%)                         | 66 (53.23)    | 61 (52.14)               | 5 (71.43)          | 0.32    |
| Hyporeflexia/partial areflexia; n (%)                | 50 (40.32)    | 48 (41.03)               | 2 (28.57)          | 0.51    |
| Normal; n (%)                                        | 8(6.45)61     | 8(6.48)                  | 0                  | 0.47    |
| Autonomic dysfunctions; n (%)                        | 43 (34.68)    | 40 (34.19)               | 3 (42.86)          | 0.64    |
| Severe; n (%)                                        | 21 (16.94)    | 20 (17.09)               | 1 (14.29)          | 0.84    |
| HR abnormality; n (%)                                | 30 (24.19)    | 28 (23.93)               | 2 (28.57)          | 0.78    |
| BP changes; n (%)                                    | 26 (20.97)    | 23 (19.66)               | 3 (42.86)          | 0.14    |
| Gastrointestinal disturbances; n (%)                 | 18 (14.52)    | 15 (12.82)               | 3 (42.86)          | 0.02*   |
| Genitourinary disturbances; n (%)                    | 15 (12.10)    | 14 (11.97)               | 1 (14.29)          | 0.85    |
| Temperature dysregulation; n (%)                     | 10 (8.06)     | 8 (6.84)                 | 2 (28.57)          | 0.04*   |
| CN involvement; n (%)                                | 60 (48.39)    | 57 (48.72)               | 3 (42.86)          | 0.76    |
| Ocular-motility; n (%)                               | 11 (8.87)     | 10 (8.55)                | 1 (14.29)          | 0.60    |
| Facial; n (%)                                        | 54 (43.55)    | 52 (44.44)               | 2 (28.57)          | 0.41    |
| Bilateral facial; n (%)                              | 30 (24.19)    | 28 (23.93)               | 2 (28.57)          | 0.78    |
| Lower CN; n (%)                                      | 10 (8.06)     | 9 (7.69)                 | 1 (14.29)          | 0.53    |
| Multiple CN involvement; n (%)                       | 15 (12.12)    | 14 (11.97)               | 1 (14.29)          | 0.85    |

Continue...
**Table 1. Continuation.**

| CSF and electrophysiological variant characteristics | Total (n=124) | GBS without TRF (n=117) | GBS with TRF (n=7) | p-value |
|-----------------------------------------------------|---------------|------------------------|--------------------|---------|
| Albuminocytologic dissociation; n (%)               | 85 (69.67)    | 79 (68.70)             | 6 (85.71)          | 0.34    |
| CSF protein level; mg/dL median (range)             | 79.9 (38.6–605) | 79.9 (38.6–605)      | 90.94 (60–176)     | 0.47    |
| Time between symptom onset and LP in days; median (range) | 7 (1–45)    | 7 (1–45)               | 7 (2–30)           | 0.60    |

**EMG classification**
- AMAN; n (%) | 4 (3.23) | 4 (3.23) | 0 | 0.62 |
- AMSAN; n (%) | 7 (5.65) | 6 (5.13) | 1 (14.29) | 0.30 |
- AIDP; n (%) | 89 (71.77) | 83 (70.94) | 6 (85.71) | 0.40 |
- Unclassified/Normal; n (%) | 18 (14.52) | 18 (15.38) | 0 | 0.26 |
- Miller Fisher; n (%) | 6 (4.84) | 6 (5.13) | 0 | 0.54 |

**Treatment and evolution**
- No treatment requirements; n (%) | 9 (7.26) | 9 (7.69) | 0 | 0.44 |
- Treatment establishment time in days; median in days (range) | 7 (1–45) | 7 (1–45) | 7 (2–30) | 0.64 |

**Initial treatment**
- Immunoglobulin; n (%) | 112 (90.32) | 106 (90.59) | 6 (85.71) | 0.67 |
- Plasmapheresis; n (%) | 3 (2.41) | 2 (1.70) | 1 (14.29) | 0.0349* |
- Combined treatment; n (%) | 10 (8.06) | 5 (4.27) | 5 (71.43) | <0.001* |
- Corticosteroids; n (%) | 5 (4.03) | 2 (1.71) | 3 (42.86) | <0.001* |
- Admission at ICU; n (%) | 18 (14.52) | 16 (13.68) | 2 (28.57) | 0.27 |
- Days in ICU; median (range) | 0 (0-120) | 0 (0-120) | 0 (0-10) | 0.38 |
- Orotracheal intubation; n (%) | 10 (8.06) | 9 (7.69) | 1 (14.29) | 0.53 |
- Non-invasive ventilation; n (%) | 5 (4.07) | 5 (4.31) | 0 | 0.57 |
- Hemodynamic support; n (%) | 6 (4.84) | 5 (4.27) | 1 (14.29) | 0.23 |
- Baseline GBS disability score; median (range) | 2 (1-5) | 2 | 4 | 0.01* |
- GBS disability score after 6 months; median (range) | 0 (0-4) | 0 | 1 | 0.08 |
- GBS disability score after 1 year; median (range) | 0 (0-4) | 0 | 0 | 0.86 |
- MRC-Sum Score at discharge; median (range) | 56 (19–60) | 56 | 53 | 0.84 |
- Final MRC-Sum Score; median (range) | 60 (20–60) | 60 | 60 | 0.70 |
- Mortality; n (%) | 1 (0.81) | 1 (0.85) | 0 | 0.80 |
- Follow-up in months; median (range) | 36 (6–156) | 36 (6–132) | 27 (6–156) | 0.47 |

AIDP: acute inflammatory demyelinating polyneuropathy; AMAN: acute motor axonal neuropathy; AMSAN: acute motor-sensory axonal neuropathy; BP: blood pressure; CSF: cerebrospinal-fluid; CN: cranial nerve; GBS: Guillain–Barré Syndrome; HR: heart rate; ICU: intensive care unit; LP: Lumbar puncture; MRC: Medical Research Council; TRF: treatment-related fluctuations.

**A-CIDP**: acute-onset chronic inflammatory demyelinating polyneuropathy; AMAN: acute motor axonal neuropathy; AMSAN: acute motor-sensory axonal neuropathy; BP: blood pressure; CSF: cerebrospinal-fluid; CN: cranial nerve; GBS: Guillain–Barré Syndrome; HR: heart rate; ICU: intensive care unit; LP: Lumbar puncture; MRC: Medical Research Council; TRF: treatment-related fluctuations.

**Figure 2. Flowchart of patient inclusion.**
There were no significant differences in past medical history or percentage of patients who had infectious triggers before GBS. However, those with TRFs had a higher frequency of infectious mononucleosis before GBS (28.57 vs. 8.55%; p = 0.01) (Table 1). One of the cases was secondary to cytomegalovirus (CMV), while the other was preceded by an Epstein Barr Virus (EBV) infection.

Neuropathic pain was the most frequent clinical manifestation in patients with TRFs (100 vs. 60.68%; p = 0.03). There were no significant differences in muscle power, sensory deficits, and cranial nerve involvement between the two groups. Dysautonomia was slightly more frequent in patients with TRFs, although the difference was not significant (85.71 vs. 68.70%; p = 0.02) and temperature dysregulation (28.57 vs. 6.84%; p = 0.04).

There were no differences in CSF findings between GBS patients with and without TRFs. The most frequent electrophysiological presentation in patients with TRFs was acute inflammatory demyelinating polyneuropathy-AIDP (85.71%); only one patient presented an axonal variant. There were no electrophysiological differences between the two groups (Table 1).

Six (85.71%) patients with TRFs received IVIg as the first treatment at a dose of 2 g/kg administered on five consecutive days. Only one (14.29%) received PE (seven sessions) (Table 2). The median delay in treatment administration from symptom onset was seven days (range 3–30 days), without differences between the two groups. The median time to first relapse was nine days (range 2–15 days). Only two patients (#4 and #5) switched the initial treatment. In three to first relapse was nine days (range 2–15 days). Only two out of differences between the two groups. The median time from symptom onset was seven days (range 3–30 days), with-

tive days. Only one (14.29%) received PE (seven sessions) at a dose of 2 g/kg administered on five consecu-

trophy of TRF: treatment-related fluctuations.

| N°/Age/Sex | T1 (days) | Initial treatment | MRC1/D1 (days) | T2 (days) | TR (days) | Relapse treatment | Total n° of TRF | TT (days) | MRC2/D2 | MRC3/D3 |
|------------|-----------|-------------------|----------------|-----------|----------|-------------------|----------------|-----------|---------|---------|
| 1/33/M     | 4         | IVIg (2 g/kg)     | 45/4           | 4         | 16       | 1st relapse: IVIg (2 g/kg) | 2               | 60        | 60/1    | 60/0    |
| 2/32/M     | 9         | IVIg (2 g/kg)     | 52/2           | 14        | 2        | 2nd relapse: corticosteroids | 1               | 35        | 60/0    | 60/0    |
| 3/71/F     | 7         | IVIg (2 g/kg)     | 58/3           | 30        | 20       | IVIg (1 g/kg) | 1               | 60        | 58/2    | 60/1    |
| 4/81/F     | 14        | IVIg (2 g/kg)     | 52/4           | 2         | 25       | PE (5 sessions) | 1               | 44        | 53/2    | -       |
| 5/53/M     | 2         | PE (7 sessions)   | 39/5           | 15        | 23       | IVIg (2 g/kg) | 1               | 38        | 54/2    | 60/0    |
| 6/57/F     | 30        | IVIg (2 g/kg)     | 50/3           | 4         | 8        | IVIg (2 g/kg)+corticosteroids | 1               | 54        | 60/1    | 60/1    |
| 7/46/M     | 3         | IVIg (2 g/kg)     | 50/4           | 9         | 8        | IVIg (2 g/kg)+corticosteroids (4 months) | 1               | 30        | 58/1    | 60/0    |

D1: GBS disability scale prior to treatment; D2: GBS disability scale at 6 months; D3: GBS disability scale at 12 month; F: female; IVIG: intravenous immunoglobulin; M: male; MRC1: Medical Research Council prior to treatment; MRC2: Medical Research Council at 6 months; MRC3: Medical Research Council at 12 months; PE: plasmapheresis; T1: start time of first treatment; T2: time from the start of relapse to the start of the second treatment; TR: time to relapse; TT: total time to stabilization or improvement; TRF: treatment-related fluctuations.

**DISCUSSION**

The frequency of TRFs in patients with GBS varies according to different series. Original reports with fewer patients suggested that TRFs could occur in up to 26% of GBS cases. Yet, some of those reports included patients who would be currently characterized as A-CIDP. The most recent series published by the International GBS Outcome Study (IGOS), which is multicenter and has a substantial sample size, showed that the prevalence of TRFs is low (5%). In our series, we observed that seven (5.64%) of 124 adult patients presented TRFs, in agreement with the results from the IGOS.

Demographic characteristics and past clinical history were similar between the GBS groups with and without TRFs (Table 1). Interestingly, the GBS group with TRFs was more frequently preceded by infectious mononucleosis secondary to CMV and EBV (28.57 vs. 8.55%; p = 0.01) and showed higher baseline disability scores (4 vs. 2; p = 0.01). It has been demonstrated that patients with GBS triggered by CMV and EBV show more severe clinical manifestations and a greater degree of disability. This could be related to the fact that the immune response mounted after the infection of these viruses causes a higher concentration of molecules associated with the activation and migration of T cells. However, in that...
report, no increased risk of TRF was observed when GBS was preceded by infection with these viruses.

On the other hand, other infectious triggers and electrophysiological variants of GBS are less associated with TRFs. GBS triggered by diarrhea, which causes axonal variants with anti-GM1 antibodies, had a lower frequency of TRFs. Our population showed similar observations since only one patient with RFT had diarrhea as an infectious trigger and one patient had an axonal variant (Table 1).

The initial clinical manifestations of GBS patients with and without TRF were similar. Nevertheless, neuropathic pain was reported by all cases of TRF. Most previous reports on TRF did not consider pain as a manifestation. Only the work by Ruts et al. showed that pain is frequent in patients with TRF (81%)

Immunotherapy with IVIg and PE are currently the most effective treatments for GBS. Both treatments have similar efficacy in reducing disability.

In conclusion, patients with GBS treated with PE more frequently occurred in patients treated with PE vs. IVIg. Hence, given the small number of GBS patients treated with PE in our series (2.4%), we cannot confirm or reject the hypothesis that TRFs more frequently occur in patients treated with PE.

There is insufficient evidence for the re-treatment of patients with GBS and TRFs. Still, physicians often choose to re-treat severe fluctuations. In our series, all patients with TRF were re-treated (Table 2). The treatment start time was similar in both groups (median of seven days), so early treatment was not decisive in relapse. In two cases, the initial treatment was changed; IVIg treatment was repeated in five patients (Table 2). There is insufficient evidence that the combination of IVIg and PE is effective and that a second IVIg course can be used, although there are prospective works in progress. Besides, three patients (42.86%) with TRFs received empirical corticosteroids in addition to IVIg treatment. It should be noted that the reason why some patients received corticosteroids temporarily was that we initially doubted whether they were not patients with A-CIDP. It is known that corticosteroid treatment is considered ineffective for GBS patients.

Nevertheless, due to the retrospective characteristics of our work, it is not possible to attribute a beneficial effect to treatment with corticosteroids.

In conclusion, in our series, patients with GBS preceded by infectious mononucleosis and who presented a higher degree of initial disability were at a higher risk of developing TRFs. Patients with TRFs were treated with PE more frequently than those without TRFs. Given the small number of patients treated with PE, we cannot affirm that the risk of TRFs increases with its use.

References

1. Osterman PO, Fagius J, Säfvenberg W, Wikström B. Early relapse of acute inflammatory polyradiculoneuropathy after successful treatment with plasma exchange. Acta Neurol Scand. 1988 Apr;77(4):273-7. https://doi.org/10.1111/j.1600-0404.1988.tb05909.x

2. Ropper AH, Albers JW, Addison R. Limited relapse in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry. 1991 Nov;54(11):957-60. https://doi.org/10.1136/jnnp.54.11.957

3. Kleyweg RP, van der Meche FG. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry. 1999 Feb;64(2):242-4. https://doi.org/10.1136/jnnp.64.2.242

4. Visser LH, Van der Meche FGA, Meuleste J, Van Doorn PA, Dutch Guillain-Barré study group. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 1998 Feb;64(2):242-4. https://doi.org/10.1136/jnnp.64.2.242

5. Ruts L, van Koningveld R, van Doorn PA. Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations. Neurology. 2005 Jul;65(1):138-40. https://doi.org/10.1212/01.wnl.0000167549.09664.b8

6. Ruts L, Drenthen J, Jacobs BC, van Doorn PA. Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome: a prospective study. Neurology. 2010 May;74(21):1680-6. https://doi.org/10.1212/ WNL.0b013e3181e07d14

7. Verboon C, Doets AY, Galassi G, Davidson A, Waheed W, Péron Y, Monges S. Current treatment practice of Guillain-Barré syndrome. Neurology. 2019 Jul;93(1):e59-e76. https://doi.org/10.1212/ WNL.0000000000007719

8. Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, et al. Regional variation of Guillain-Barré syndrome. Brain. 2018 Oct;141(10):2866-77. https://doi.org/10.1093/brain/awy232

9. Kimura J. Electrodiagnosis in diseases of nerve and muscle: principles and practice. 4th Edition. Oxford: Oxford University Press; 2001. https://doi.org/10.1093/med/9780199738687.001.0001

10. Hadden RD, Cornblath DR, Hughes RA, Ziemke HR, Toyka KV, Swan AV. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome: Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol. 1998 Nov;44(5):780-8. https://doi.org/10.1002/ana.410440512

11. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet. 1978 Oct;2(8093):750-3. https://doi.org/10.1016/s0140- 6736(78)92644-2
12. Hadden RDM, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J, et al. Preceding infections, immune factors, and outcome in Guillain–Barré syndrome. Neurology. 2001 Mar;56(6):758-65. https://doi.org/10.1212/wnl.56.6.758

13. Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2002;(2):CD001798. https://doi.org/10.1002/14651858.CD001798

14. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2012 Jul;(7):CD002063. https://doi.org/10.1002/14651858.CD002063.pub5

15. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet. 1997 Jan;349(9047):225-30.

16. Walgaard C, Jacobs BC, Lingsma HF, Steyerberg DR, van Doorn PA. Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): protocol for a double-blind randomized, placebo-controlled clinical trial. J Peripher Nerv Syst. 2018 Dec;23(4):210-5. https://doi.org/10.1111/jns.12286

17. Verboon C, van Doorn PA, Jacobs BC. Treatment dilemmas in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):346-52. https://doi.org/10.1136/jnnp-2016-314862

18. van der Meché FG, Schmitz Pi. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome: Dutch Guillain-Barre Study Group. N Engl J Med. 1992 Apr;326(17):1123-9. https://doi.org/10.1056/NEJM199204233261705

19. Hughes RA, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2016 Oct;10(10):CD001446. https://doi.org/10.1002/14651858.CD001446.pub5